Iradimed (NASDAQ:IRMD) Releases FY 2025 Earnings Guidance

Iradimed (NASDAQ:IRMD) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 1.710-1.810 for the period, compared to the consensus earnings per share estimate of 1.750. The company issued revenue guidance of $78.0 million-$82.0 million, compared to the consensus revenue estimate of $80.7 million. Iradimed also updated its Q1 2025 guidance to 0.390-0.430 EPS.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded shares of Iradimed from a “strong-buy” rating to a “buy” rating in a report on Thursday.

Iradimed Stock Performance

IRMD stock traded down $6.16 during midday trading on Thursday, reaching $54.32. The company’s stock had a trading volume of 41,046 shares, compared to its average volume of 39,609. The firm has a market capitalization of $688.23 million, a price-to-earnings ratio of 37.13 and a beta of 0.82. Iradimed has a 1 year low of $40.18 and a 1 year high of $63.29. The stock has a fifty day simple moving average of $57.16 and a two-hundred day simple moving average of $52.02.

Iradimed (NASDAQ:IRMD) last announced its quarterly earnings data on Thursday, February 13th. The medical equipment provider reported $0.40 earnings per share for the quarter, missing analysts’ consensus estimates of $0.45 by ($0.05). Iradimed had a net margin of 26.12% and a return on equity of 23.99%. As a group, analysts forecast that Iradimed will post 1.52 EPS for the current fiscal year.

Insider Activity at Iradimed

In related news, CFO John Glenn sold 2,500 shares of Iradimed stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $54.18, for a total value of $135,450.00. Following the completion of the sale, the chief financial officer now directly owns 4,383 shares in the company, valued at $237,470.94. The trade was a 36.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 37.10% of the stock is owned by company insiders.

Iradimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.